Provexis (CHIX:PXSL) Debt-to-Equity: 0.00 (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Provexis Debt-to-Equity?

Provexis CHIX:PXSL +3.00% Debt-to-Equity is 0.00 as of Sep. 2025. The stock has 1 warning sign investors should review. Among 811 Drug Manufacturers companies, Provexis ranks worse than 123304.44% on this metric.

Provexis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was £0.00 Mil. Provexis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was £0.00 Mil. Provexis's Total Stockholders Equity for the quarter that ended in Sep. 2025 was £1.15 Mil. Provexis's debt to equity for the quarter that ended in Sep. 2025 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Provexis's Debt-to-Equity or its related term are showing as below:

CHIX:PXSl's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.27
* Ranked among companies with meaningful Debt-to-Equity only.

Provexis  (CHIX:PXSl) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Provexis Debt-to-Equity Related Terms

Provexis Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Provexis's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Provexis Debt-to-Equity Chart

Provexis Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Provexis Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CHIX:PXSL vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Provexis's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Provexis Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Provexis's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Provexis's Debt-to-Equity falls into.


Provexis Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Provexis's Debt to Equity Ratio for the fiscal year that ended in Mar. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 1.298
=0.00

Provexis's Debt to Equity Ratio for the quarter that ended in Sep. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 1.145
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Provexis (CHIX:PXSL) has a Debt-to-Equity of 0.00 as of Sep. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Provexis and its competitors. According to the industry distribution chart, Provexis ranks #999999 out of 811 companies in the Drug Manufacturers industry.
Is Provexis' Debt-to-Equity too high?
Provexis' current Debt-to-Equity is 0.00. Based on the distribution chart, Provexis ranks #999999 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Provexis' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Provexis ranks #999999 out of 811 companies for Debt-to-Equity. This places Provexis in the lower half of its industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Provexis and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Provexis's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provexis stock overvalued right now?
Provexis (CHIX:PXSL) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Provexis (CHIX:PXSL), the current Debt-to-Equity is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Provexis Business Description

Other Exchanges PXS:UKNZCA:Germany
Address 2 Blagrave Street, I Ford, Reading, Berkshire, GBR, RG1 1AZ
Provexis PLC is engaged in developing, licensing and selling the proprietary, scientific Fruitflow heart-health functional food ingredient for the global functional food sector. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.